58 related articles for article (PubMed ID: 3352696)
1. Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma.
Pedersen-Bjergaard J; Ersbøll J; Hansen VL; Sørensen BL; Christoffersen K; Hou-Jensen K; Nissen NI; Knudsen JB; Hansen MM
N Engl J Med; 1988 Apr; 318(16):1028-32. PubMed ID: 3352696
[TBL] [Abstract][Full Text] [Related]
2. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis.
Talar-Williams C; Hijazi YM; Walther MM; Linehan WM; Hallahan CW; Lubensky I; Kerr GS; Hoffman GS; Fauci AS; Sneller MC
Ann Intern Med; 1996 Mar; 124(5):477-84. PubMed ID: 8602705
[TBL] [Abstract][Full Text] [Related]
3. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma.
Travis LB; Curtis RE; Glimelius B; Holowaty EJ; Van Leeuwen FE; Lynch CF; Hagenbeek A; Stovall M; Banks PM; Adami J
J Natl Cancer Inst; 1995 Apr; 87(7):524-30. PubMed ID: 7707439
[TBL] [Abstract][Full Text] [Related]
4. Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphoma.
Geurts YM; Neppelenbroek SIM; Aleman BMP; Janus CPM; Krol ADG; van Spronsen DJ; Plattel WJ; Roesink JM; Verschueren KMS; Zijlstra JM; Koene HR; Nijziel MR; Schimmel EC; de Jongh E; Ong F; Te Boome LCJ; van Rijn RS; Böhmer LH; Ta BDP; Visser HPJ; Posthuma EFM; Bilgin YM; Muller K; van Kampen D; So-Osman C; Vermaat JSP; de Weijer RJ; Kersten MJ; van Leeuwen FE; Schaapveld M
ESMO Open; 2024 Feb; 9(2):102248. PubMed ID: 38350338
[TBL] [Abstract][Full Text] [Related]
5. Secondary malignancies in non-Hodgkin lymphoma survivors: 40 years of follow-up assessed by treatment modality.
Parsons MW; Rock C; Chipman JJ; Shah HR; Hu B; Stephens DM; Tao R; Tward JD; Gaffney DK
Cancer Med; 2023 Feb; 12(3):2624-2636. PubMed ID: 36812123
[TBL] [Abstract][Full Text] [Related]
6. A review of the risks of long-term consequences associated with components of the CHOP chemotherapy regimen.
Watson C; Gadikota H; Barlev A; Beckerman R
J Drug Assess; 2022; 11(1):1-11. PubMed ID: 35693477
[TBL] [Abstract][Full Text] [Related]
7. Optimal body mass index cut-point for predicting recurrence-free survival in patients with non-muscle-invasive urothelial carcinoma of bladder.
Yonekura S; Terauchi F; Hoshi K; Yamaguchi T; Kawai S
Oncol Lett; 2018 Sep; 16(3):4049-4056. PubMed ID: 30128027
[TBL] [Abstract][Full Text] [Related]
8. Incidence and Survival of urothelial carcinoma of the urinary bladder in Norway 1981-2014.
Andreassen BK; Aagnes B; Gislefoss R; Andreassen M; Wahlqvist R
BMC Cancer; 2016 Oct; 16(1):799. PubMed ID: 27737647
[TBL] [Abstract][Full Text] [Related]
9. Acrolein- and 4-Aminobiphenyl-DNA adducts in human bladder mucosa and tumor tissue and their mutagenicity in human urothelial cells.
Lee HW; Wang HT; Weng MW; Hu Y; Chen WS; Chou D; Liu Y; Donin N; Huang WC; Lepor H; Wu XR; Wang H; Beland FA; Tang MS
Oncotarget; 2014 Jun; 5(11):3526-40. PubMed ID: 24939871
[TBL] [Abstract][Full Text] [Related]
10. Cytological Diagnosis of Small Cell Carcinoma of Urinary Bladder in a Patient with CLL.
Güler Şimşek G; Güreşçi S; Oğuz U; Unsal A
Cell J; 2014 Feb; 16(1):95-8. PubMed ID: 24518979
[TBL] [Abstract][Full Text] [Related]
11. Pathobiology and chemoprevention of bladder cancer.
Tanaka T; Miyazawa K; Tsukamoto T; Kuno T; Suzuki K
J Oncol; 2011; 2011():528353. PubMed ID: 21941546
[TBL] [Abstract][Full Text] [Related]
12. Treating rheumatic patients with a malignancy.
Elandt K; Aletaha D
Arthritis Res Ther; 2011 Jun; 13(3):223. PubMed ID: 21722342
[TBL] [Abstract][Full Text] [Related]
13. Genitourinary long-term outcomes for childhood cancer survivors.
Shnorhavorian M; Friedman DL; Koyle MA
Curr Urol Rep; 2009 Mar; 10(2):134-7. PubMed ID: 19239818
[TBL] [Abstract][Full Text] [Related]
14. A study on the genotoxic effects of 8-Cl-cAMP on human lymphocytes in vitro.
Bajić V; Djelić N; Spremo-Potparević B; Zivković L; Milićević Z
Genetika; 2008 May; 44(5):631-7. PubMed ID: 18672796
[TBL] [Abstract][Full Text] [Related]
15. Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.
Kempen JH; Gangaputra S; Daniel E; Levy-Clarke GA; Nussenblatt RB; Rosenbaum JT; Suhler EB; Thorne JE; Foster CS; Jabs DA; Helzlsouer KJ
Am J Ophthalmol; 2008 Dec; 146(6):802-12.e1. PubMed ID: 18579112
[TBL] [Abstract][Full Text] [Related]
16. Risk-based health monitoring of childhood cancer survivors: a report from the Children's Oncology Group.
Nunez SB; Mulrooney DA; Laverdiere C; Hudson MM
Curr Oncol Rep; 2007 Nov; 9(6):440-52. PubMed ID: 17991351
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology of urinary bladder cancer: from tumor development to patient's death.
Murta-Nascimento C; Schmitz-Dräger BJ; Zeegers MP; Steineck G; Kogevinas M; Real FX; Malats N
World J Urol; 2007 Jun; 25(3):285-95. PubMed ID: 17530260
[TBL] [Abstract][Full Text] [Related]
18. Chemoprevention of bladder cancer.
Golijanin DJ; Kakiashvili D; Madeb RR; Messing EM; Lerner SP
World J Urol; 2006 Nov; 24(5):445-72. PubMed ID: 17048030
[No Abstract] [Full Text] [Related]
19. Cyclophosphamide is contraindicated in patients with a history of transitional cell carcinoma.
Volkmer BG; Seidl-Schlick EM; Bach D; Romics I; Kleinschmidt K
Clin Rheumatol; 2005 Aug; 24(4):319-23. PubMed ID: 16034647
[TBL] [Abstract][Full Text] [Related]
20. Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide.
Knight A; Askling J; Granath F; Sparen P; Ekbom A
Ann Rheum Dis; 2004 Oct; 63(10):1307-11. PubMed ID: 15130900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
